rawfin.tv
FDA Extends Capricor DMD Therapy Review; Merck/Moderna Cancer Vaccine Shows Promise
MarketsstocksAI Generated

FDA Extends Capricor DMD Therapy Review; Merck/Moderna Cancer Vaccine Shows Promise

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

The FDA has extended its review period for Capricor Therapeutics' Duchenne muscular dystrophy cell therapy, creating uncertainty for the company. Meanwhile, the cancer vaccine developed by Merck and Moderna continues to demonstrate positive results.

biotechnologypharmaceuticalsFDA-reviewcancer-vaccineDMD-therapy

Related Articles

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks